Literature DB >> 3093415

Effects of dose and scheduling on growth delay of the Lewis lung carcinoma produced by the perfluorochemical emulsion, Fluosol-DA.

B A Teicher, C M Rose.   

Abstract

The perfluorochemical emulsion, Fluosol-DA, combined with breathing a 95% oxygen/5% carbon dioxide atmosphere enhances the response of several rodent tumors. B6D2F1/J mice bearing Lewis lung tumors, measuring 50-100 mm3 were treated with 4, 8 and 12 ml/kg of Fluosol-DA intravenously each morning. Three Gy fractions twice per day were employed and carbogen breathing was maintained 1 hr prior to and during each X ray treatment. The dose modifying factors were 1.42 +/- 0.16 at 4 ml/kg, 1.85 +/- 0.23 at 8 ml/kg, and 2.17 +/- 0.34 at 12 ml/kg. In a second experiment, a single dose of Fluosol-DA (12 ml/kg) was administered on day 1 to B6D2F1/J male mice, bearing established subcutaneous Lewis lung tumors, as described above. X rays were delivered in 2, 3, or 4 Gy fractions once per day for five days. The dose modifying effect was 2.60 +/- 0.54. The effect of this treatment program was the same as that seen with single dose radiation. These experiments demonstrate that Fluosol-DA need not be administered with every fraction to produce an improved treatment outcome with fractionated X rays.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3093415     DOI: 10.1016/0360-3016(86)90161-6

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  6 in total

1.  Fluosol-DA/carbogen with lonidamine or pentoxifylline as modulators of alkylating agents in the FSaIIC fibrosarcoma.

Authors:  B A Teicher; T S Herman; J Tanaka; B Dezube; A Pardee; E Frei
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

2.  The effect of fluosol-DA and oxygenation status on the activity of cyclophosphamide in vivo.

Authors:  B A Teicher; T S Herman; S A Holden; K N Cathcart
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

3.  Effect of fluosol-DA/carbogen on etoposide/alkylating agent antitumor activity.

Authors:  B A Teicher; S D Bernal; S A Holden; K N Cathcart
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 4.  Hypoxia and drug resistance.

Authors:  B A Teicher
Journal:  Cancer Metastasis Rev       Date:  1994-06       Impact factor: 9.264

5.  Effect of a bovine hemoglobin preparation on the response of the FSaIIC fibrosarcoma to chemotherapeutic alkylating agents.

Authors:  B A Teicher; T S Herman; R E Hopkins; K Menon
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

6.  Nicotinamide, Fluosol DA and Carbogen: a strategy to reoxygenate acutely and chronically hypoxic cells in vivo.

Authors:  D J Chaplin; M R Horsman; D S Aoki
Journal:  Br J Cancer       Date:  1991-01       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.